January 31, 2019

The comprehensive reis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis’ fourth-quarter results call, Nbe a spend of around 5% of Novartis’ market cap on M&A each year, which would equate to around $10 billion, as the process of “redesigning” the company around advanced therapy platforms and data science continues.

Last year’s additions included gene therapy company AveXis, bought for $8.7 bil specialists Endocyte which cost $2.1 billion, and Narasimhan said there was an appetite in picking up additional assets in “new technology areas [and] advanced therapy platforms.”

https://phavartis-spent-15bn-on-ma-last-year-with-mo

Nordic Nanovector is according to The Pharmaletter. Hematological cancer specialist


---------------------------------------------------------------------------------

Nordic Nanovecter is applying Research partner. Ist large medicine capital. The competition between Norvatris is described in Q3 from 6 november 2018

Big pharma in the alps

https://www.swi

Hva slagartner Nordic Nanovecter søker etter vet ikke jeg. Det vil not meddele børsen om n faller på plass, samt at de vil nok oppdatere aksjonærene om fremgangen i En glemme dette året

Ellers så har Fro veldig bra, tuller med e her hos Trygve, men det var like ilisi om til gull. Tro det elle fjernet dritten fra børsen.